| Acute Leukemia |
1 |
1 |
| Stem Cell Research and Therapy |
0 |
0.95 |
| Transplantation |
0 |
0.9 |
| Anaphylaxis |
0 |
0.85 |
| Graft Versus Host Disease and Transplant Complications |
0 |
0.85 |
| Allograft |
0 |
0.68 |
| Cell Transplantation |
0 |
0.68 |
| Transplant Program |
0 |
0.63 |
| Bone Marrow Transplant |
0 |
0.55 |
| Acute Myeloblastic Leukemia |
0 |
0.29 |
| Leukemia |
0 |
0.29 |
| Chemotherapy |
0 |
0.21 |
| Genomic Medicine |
0 |
0.15 |
| Toxicology |
0 |
0.15 |
| Cancer |
0 |
0.14 |
| Europe |
0 |
0.14 |
| Hematology |
0 |
0.14 |
| Residual Disease |
0 |
0.14 |
| Platelet Count |
0 |
0.12 |
| Bone Marrow |
0 |
0.1 |
| Graft Versus Host Disease |
0 |
0.1 |
| Anemia |
0 |
0.07 |
| Bone |
0 |
0.07 |
| Global Development |
0 |
0.07 |
| Graft |
0 |
0.07 |
| Hematologic Malignancies |
0 |
0.07 |
| Neutrophils |
0 |
0.07 |
| Oncogene |
0 |
0.07 |
| Preventive Screening |
0 |
0.07 |
| Prognosis |
0 |
0.07 |
| Prophylaxis |
0 |
0.07 |
| Refractory |
0 |
0.07 |
| Remission |
0 |
0.07 |
| Tyrosine Kinase |
0 |
0.07 |